Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.
Natural Killer T-cell Lymphoma
DRUG: Golidocitinib|DRUG: Benmelstobart
Objective response rate(ORR), The proportion of patients who achieve complete remission (CR) or partial remission (PR) as the best response., 2 years
Complete Response(CR), Defined as the proportion of patients who achieve complete remission as the best response, 2 years|Duration of Response(DOR), To investigate the preliminary anti-tumor efficacy, Up to 4 years|Progression-free survival(PFS), To investigate the preliminary anti-tumor efficacy, Up to 4 years|Overall survival(OS), To investigate the preliminary anti-tumor efficacy, Up to 4 years|Incidence and severity of adverse events (AE) , Serious adverse event (SAE) and immune-related adverse event (irAE), To identify the incidence of AE, SAE, and irAE., Through study completion, up tp 2 years.
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.